These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17306443)

  • 1. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
    Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
    Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
    Bjartell A; Paju A; Zhang WM; Gadaleanu V; Hansson J; Landberg G; Stenman UH
    Prostate; 2005 Jun; 64(1):29-39. PubMed ID: 15651064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
    Edwards J; Leung HY
    Eur Urol; 2007 Dec; 52(6):1680-1. PubMed ID: 17306442
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
    Schalken J
    Eur Urol; 2007 Dec; 52(6):1679. PubMed ID: 17306439
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
    Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
    Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
    Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
    BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Monsef N; Helczynski L; Lundwall A; Påhlman S;
    Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgens induce CD-9 in human prostate tissue.
    Chuan Y; Pang ST; Bergh A; Norstedt G; Pousette A
    Int J Androl; 2005 Oct; 28(5):291-6. PubMed ID: 16128989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of LMO2 expression in the progression of prostate cancer.
    Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
    J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
    Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
    Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and nuclear localization of ErbB3 in prostate cancer.
    Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
    Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C
    Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
    Meyer-Siegler KL; Iczkowski KA; Vera PL
    BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
    Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA
    Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
    Chua CW; Chiu YT; Yuen HF; Chan KW; Wang X; Ling MT; Wong YC
    APMIS; 2010 Dec; 118(12):918-26. PubMed ID: 21091772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
    Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
    J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.